Advice
in the absence of a submission from the holder of the marketing authorisation:
ravulizumab (Ultomiris®) is not recommended for use within NHSScotland.
Indication under review: treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody-positive.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice236KB (PDF)
Medicine details
- Medicine name:
- ravulizumab (Ultomiris)
- SMC ID:
- SMC2658
- Indication:
Treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody-positive.
- Pharmaceutical company
- Alexion Pharma UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 February 2024